Last reviewed · How we verify
Secondary Prophylaxis
This drug is used to prevent the recurrence of certain infections.
This drug is used to prevent the recurrence of certain infections. Used for Prevention of recurrent meningococcal disease.
At a glance
| Generic name | Secondary Prophylaxis |
|---|---|
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Secondary prophylaxis involves administering a medication to prevent the recurrence of an infection that has already been treated. This approach is often used for conditions such as meningitis or sepsis, where the risk of recurrence is high.
Approved indications
- Prevention of recurrent meningococcal disease
Common side effects
- Allergic reactions
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children (NA)
- V-CARE (Virtual Care After REsuscitation) (NA)
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 (PHASE3)
- Critical Food Ingredients on Immunocompetence to Prevent the Risk and Development of Obesity/Metabolic Syndrome (NA)
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Secondary Prophylaxis CI brief — competitive landscape report
- Secondary Prophylaxis updates RSS · CI watch RSS
- Children's Hospital Medical Center, Cincinnati portfolio CI